// App-Quantinova.ai

7014 : Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

Researchers

Presenter

  • Tapan M. Kadia

Principal Investigators

  • Jorge E. Cortes

  • Ahmad Ghorab

  • Farhad Ravandi

  • Elias Jabbour

  • Naval Guastad Daver

  • Yesid Alvarado

  • Maro Ohanian

  • Marina Konopleva

  • Hagop M. Kantarjian

Medical Centers

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Leukemia Department, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02532231

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved